Nirogacestat

Small molecule

Also known as PF-03084014

Approvedregulatory verdict

Evidence outlook

Approved: Desmoid Tumors

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also in development:Multiple Myeloma · Phase 1/2 · investigational in the US

Also approved (1)
EU
  • Ogsiveo as monotherapy is indicated for the treatment of adult patients with progressing desmoid tumours who require systemic treatment.
Product first approved 2025EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Desmoid Tumors
Phase 2 (12)
Desmoid Tumors
NCT04195399 · Children's Oncology Group
2020-10-07 – 2032-12-31 · Desmoid Fibromatosis, Recurrent Desmoid Fibromatosis, Unresectable Desmoid Fibromatosis
What this study did
NCT07170644 · SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
2025-08-08 – 2029-10-09 · Desmoid Tumor, Aggressive Fibromatosis
What this study did
NCT05949099 · Nam Bui
2023-08-15 – 2028-02-01 · Desmoid Tumor
What this study did
NCT05879146 · M.D. Anderson Cancer Center
2024-11-26 – 2028-01-31 · Tumor
What this study did
NCT01981551 · National Cancer Institute (NCI)
2013-10-31 – 2023-12-01 · Desmoid Tumors, Aggressive Fibromatosis
What this study did
Multiple Myeloma
NCT05090566 · Pfizer
2021-10-27 – 2026-03-11 · Multiple Myeloma
What this study did
Other / comorbidity
NCT07539454 · AIDS Malignancy Consortium
2026-10-13 – 2030-02-17 · AIDS-Related Kaposi Sarcoma, Skin Kaposi Sarcoma
What this study did
NCT05348356 · SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
2022-08-30 – 2025-07-14 · Ovarian Granulosa-Stromal Tumor, Ovarian Granulosa Cell Tumor, Ovarian Cancer
What this study did
NCT02338531 · Jules Bordet Institute
2015-06 – 2018-12 · Breast Cancer
What this study did
NCT02299635 · Pfizer
2015-02-03 – 2016-01-14 · Triple Negative Breast Neoplasms
What this study did
NCT02137564 · AIDS Malignancy Consortium
2015-07 – 2015-07 · AIDS-related Kaposi Sarcoma, HIV Infection, Recurrent Kaposi Sarcoma
What this study did
Phase 1/2 (5)
Multiple Myeloma
NCT04126200 · GlaxoSmithKline
2019-10-07 – 2027-03-11 · Multiple Myeloma
What this study did
NCT07150104 · GlaxoSmithKline
2022-08-31 – 2027-03-11 · Multiple Myeloma
What this study did
NCT05573802 · Hellenic Society of Hematology
2023-07-14 – 2026-10-31 · Multiple Myeloma, Neoplasms, Neoplasm, Plasma Cell, Gammopathy, Monoclonal, Paraproteinemias, Blood Protein Disorders, Haematologic Disease, Corneal Disease
What this study did
Phase 1 (10)
Multiple Myeloma
NCT04722146 · Janssen Research & Development, LLC
2021-03-12 – 2027-10-13 · Multiple Myeloma
What this study did
NCT05556798 · Memorial Sloan Kettering Cancer Center
2022-10-04 – 2027-10 · Multiple Myeloma
What this study did
NCT04093596 · Allogene Therapeutics
2019-09-23 – 2025-01-27 · Relapsed/Refractory Multiple Myeloma
What this study did
NCT04171843 · Precision BioSciences, Inc.
2020-04-30 – 2022-10-19 · Relapsed/Refractory Multiple Myeloma
What this study did
Other / comorbidity
NCT07259330 · SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
2025-10-27 – 2026-03-27 · Healthy
What this study did
NCT07171619 · SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
2025-08-21 – 2025-11-10 · Healthy
What this study did
NCT00878189 · Pfizer
2009-06-25 – 2016-11-22 · Neoplasms by Histologic Type
What this study did
NCT02462707 · Pfizer
2015-07 – 2016-10 · Advanced Solid Tumors
What this study did
NCT01876251 · Pfizer
2013-11-04 – 2015-12-24 · Breast Cancer Metastatic
What this study did
Phase 4 (1)
Desmoid Tumors
NCT07176689 · SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
2025-09-17 – 2031-02-26 · Desmoid Tumor, Aggressive Fibromatosis
What this study did

Competitive landscape

Other Gamma-secretase (presenilin complex) drugs

Varegacestat. Compare all 2 Gamma-secretase (presenilin complex) drugs

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Desmoid Tumors: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Nirogacestat: this drugApprovedSmall moleculeGamma-secretase (presenilin complex)Reliable signalNo reviewed efficacy summary in this indication
VaregacestatPhase 2/3Small moleculeGamma-secretase (presenilin complex)Partial signal
NCT04871282: Primary endpoint, progression-free survival vs placebo: HR 0.16 (95% CI 0.071-0.375; p<0.0001); confirmed ORR 56% vs 9% (RINGSIDE, 2025-12-15).

Upcoming events

(7 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Nirogacestat to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (3)
January 2027 (1)
Phase 2Desmoid TumorsRecruiting
Est. primary completion 2027-01-31 · NCT05879146 · CT.gov ↗
What to watch
May 2027 (1)
Phase 2Desmoid TumorsActive not recruiting
Est. primary completion 2027-05-28 · NCT07170644 · CT.gov ↗
What to watch
October 2027 (1)
Phase 1Multiple MyelomaActive not recruiting
Est. primary completion 2027-10 · NCT05556798 · CT.gov ↗
What to watch
2028 (2)
February 2028 (1)
Phase 2Desmoid TumorsRecruiting
Est. primary completion 2028-02-01 · NCT05949099 · CT.gov ↗
What to watch
March 2028 (1)
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2028-03-25 · NCT05137054 · CT.gov ↗
What to watch
2030 (1)
February 2030 (1)
Phase 2AIDS-Related Kaposi Sarcoma, Skin Kaposi SarcomaRecruiting
Est. primary completion 2030-02-17 · NCT07539454 · CT.gov ↗
What to watch
2031 (1)
February 2031 (1)
Phase 4Desmoid TumorsRecruiting
Est. primary completion 2031-02-26 · NCT07176689 · CT.gov ↗
What to watch

See the full readout calendar ↗